Warnex Inc.
TSX : WNX

Warnex Inc.

April 30, 2008 15:22 ET

Warnex Appoints Two New Directors: Gilles Gagnon and Mattie Chinks

LAVAL, QUEBEC--(Marketwire - April 30, 2008) - Warnex Inc. (TSX:WNX) is pleased to announce that, following it Annual General Meeting of Shareholders, Mr. Gilles Gagnon and Mr. Mattie Chinks have joined the Board of Directors of Warnex.

"It is with great pleasure that we welcome these two new members to Warnex's Board of Directors. With the transition of Warnex's focus last year from a research and development driven company to one focused on contract research services, we have modified the composition of our Board to reflect these changes," said Mark Busgang, President and CEO of Warnex. "With his extensive knowledge of the healthcare and pharmaceutical industry as well as his experience in mergers and acquisitions, Mr. Gagnon will provide valuable insight for Warnex's strategic growth plan. Mr. Chinks complements the Board with his experience in the management of a client-oriented manufacturing business, which is in line with Warnex's new business model."

Mr. Gilles Gagnon is a consultant with over 25 years experience within the field of health, especially in the hospital environment and pharmaceutical industry, where he held several executive positions and participated to the launch of many innovative drugs. Mr. Gagnon has held several senior executive positions, including President and COO, then CEO at AEterna Zentaris, VP External Affairs at Novartis Pharmaceuticals, and Executive Director, Corporate Planning and Administration at Sandoz Canada, Inc. Throughout his career, in addition to general management functions, he has been particularly involved in corporate development, mergers and acquisitions, as well as marketing functions.

Mr. Chinks is President of Avmor Ltd., a leading company in the development and manufacturing of professional cleaning and sanitation products and cleaning solutions. He has over 25 years experience in sales and marketing, product development, general management and corporate development. Mr. Chinks has previously served as President and International Director of the International Sanitary Supply Association and currently sits on the Board of Directors of The Royal Victoria Hospital Foundation and Cannon Hygiene Canada.

About Warnex

Warnex (www.warnex.ca) is a life sciences company devoted to protecting public health by providing laboratory services to the pharmaceutical and healthcare sectors. Warnex's analytical services division provides pharmaceutical and biotechnology companies with a variety of quality control services, including traditional chemistry, chromatography, microbiology, method development and validation, and stability studies. Warnex's bioanalytical services division specializes in bioequivalence and bioavailability studies for clinical trials. Warnex's medical laboratories division focuses on genetic and biochemical testing for the healthcare industry and has extensive expertise in genetic testing for human identification, molecular diagnostics, and pharmacogenetics.

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained in this news release are forward-looking and are subject to numerous risks and uncertainties, known and unknown. For information identifying known risks and uncertainties, relating to financial resources, government regulations, laboratory facilities, suppliers, employees, key customers and business partners, foreign currency risk, credit risk, volatility of share price, and other important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the heading Risks and Uncertainties in Warnex's most recent Management's Discussion and Analysis, which can be found at www.sedar.com. Consequently, actual results may differ materially from the anticipated results expressed in these forward-looking statements.

Contact Information